

# Takashi Matsui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2127963/publications.pdf>

Version: 2024-02-01

50  
papers

3,953  
citations

304368

22  
h-index

214527

47  
g-index

53  
all docs

53  
docs citations

53  
times ranked

4556  
citing authors

#	ARTICLE	IF	CITATIONS
1	Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo. <i>Circulation</i> , 2001, 104, 330-335.	1.6	673
2	Restoration of Contractile Function in Isolated Cardiomyocytes From Failing Human Hearts by Gene Transfer of SERCA2a. <i>Circulation</i> , 1999, 100, 2308-2311.	1.6	454
3	Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart. <i>Journal of Biological Chemistry</i> , 2002, 277, 22896-22901.	1.6	391
4	Adenoviral Gene Transfer of Activated Phosphatidylinositol 3-kinase and Akt Inhibits Apoptosis of Hypoxic Cardiomyocytes In Vitro. <i>Circulation</i> , 1999, 100, 2373-2379.	1.6	367
5	Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H659-H668.	1.5	234
6	Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. <i>Journal of Molecular and Cellular Cardiology</i> , 2005, 38, 63-71.	0.9	228
7	PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. <i>Journal of Clinical Investigation</i> , 2005, 115, 2128-2138.	3.9	221
8	Prospects for Gene Therapy for Heart Failure. <i>Circulation Research</i> , 2000, 86, 616-621.	2.0	151
9	Guidelines for evaluating myocardial cell death. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H891-H922.	1.5	135
10	Cardiac mTOR protects the heart against ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H75-H85.	1.5	123
11	mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. <i>American Journal of Physiology - Cell Physiology</i> , 2010, 299, C1256-C1266.	2.1	118
12	Pathological Roles of Iron in Cardiovascular Disease. <i>Current Drug Targets</i> , 2018, 19, 1068-1076.	1.0	116
13	Adenoviral Gene Transfer of Phospholamban in Isolated Rat Cardiomyocytes. <i>Circulation Research</i> , 1997, 81, 145-153.	2.0	99
14	Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. <i>Cell Cycle</i> , 2003, 2, 220-3.	1.3	79
15	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 33.	1.2	66
16	Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study. <i>Respiration</i> , 2018, 96, 323-329.	1.2	63
17	Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0140437.	1.1	53
18	The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2017, 17, 38.	1.7	51

#	ARTICLE	IF	CITATIONS
19	Effects of chronic Akt activation on glucose uptake in the heart. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E789-E797.	1.8	49
20	The Cardiomyocyte as a Source of Cytokines in Cardiac Injury. Journal of Cell Science & Therapy, 2011, 5, .	0.3	48
21	Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1530-H1539.	1.5	34
22	Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2011818.	2.8	26
23	Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nature Communications, 2021, 12, 1032.	5.8	26
24	Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemotherapy and Pharmacology, 2019, 84, 147-153.	1.1	17
25	Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2022, 71, 203-217.	2.0	16
26	The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction. Cells, 2022, 11, 1399.	1.8	15
27	Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1031-1038.	1.1	14
28	Myocyte injury along myofibers in left ventricular remodeling after myocardial infarction. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 951-955.	0.5	10
29	Assessment of PI-3 Kinase and Akt in Ischemic Heart Diseases in Diabetes. Methods in Molecular Medicine, 2007, 139, 329-338.	0.8	10
30	Cone beam computed tomography of plastinated hearts for instruction of radiological anatomy. Surgical and Radiologic Anatomy, 2016, 38, 843-853.	0.6	8
31	Clinical Outcomes of Anti-programmed Death-1 Antibody-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Comprehensive Clinical Medicine, 2020, 2, 570-578.	0.3	8
32	Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms. Anticancer Research, 2018, 38, 5937-5941.	0.5	7
33	Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Respiratory Investigation, 2018, 56, 179-183.	0.9	5
34	Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function. Acta Oncologica, 2018, 57, 1232-1239.	0.8	5
35	Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Investigational New Drugs, 2021, 39, 210-216.	1.2	4
36	Cardiac signal transduction. Journal of Nuclear Cardiology, 2000, 7, 63-71.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Three-dimensional myocardial scarring along myofibers after coronary ischemia-reperfusion revealed by computerized images of histological assays. <i>Physiological Reports</i> , 2014, 2, e12072.	0.7	3
38	Rhinosinusitis and disseminated cutaneous infection caused by <i>Mycobacterium chelonae</i> in an immunocompromised patient. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 691-694.	0.8	3
39	Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , 2018, 35, 108.	1.2	3
40	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 531-537.	1.2	3
41	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. <i>BMC Cancer</i> , 2021, 21, 57.	1.1	3
42	Targeting ischemic cardiac dysfunction through gene transfer. <i>Current Atherosclerosis Reports</i> , 2003, 5, 191-195.	2.0	2
43	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	0.8	2
44	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211083.	1.1	2
45	The effects of Tel2 on cardiomyocyte survival. <i>Life Sciences</i> , 2019, 232, 116665.	2.0	1
46	The role of ubiquitin in cardiac ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H583-H585.	1.5	1
47	mTOR-mediated calcium transients affect cardiac function in ex vivo ischemia-reperfusion injury. <i>Physiological Reports</i> , 2021, 9, e14807.	0.7	1
48	Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer with stereotactic radiotherapy: A multi-institutional study. <i>Journal of Clinical Oncology</i> , 2014, 32, 7591-7591.	0.8	1
49	Retrospective analysis comparing pulmonary toxicity between S-1 and docetaxel in non-small-cell lung cancer patients with preexisting interstitial lung disease. <i>Journal of Clinical Oncology</i> , 2015, 33, e19105-e19105.	0.8	1
50	A Case of Small Cell Lung Cancer in Complete Remission for Nine Years After Recurrence by Solitary Brain Metastasis and Treatment with Stereotactic Irradiation. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 775-780.	0.0	0